Brief: Immuneonco Biopharmaceuticals (Shanghai) Receives FDA Approval For IND Application Of IMM0306 For Phase IB/II SLE Trial
21/08/2026 16:44
BRIEF-Immuneonco Biopharmaceuticals (Shanghai) Receives FDA Approval For IND Application Of IMM0306 For Phase IB/II SLE Trial Aug 21 (Reuters) - ImmuneOnco Biopharmaceuticals (Shanghai) Inc 1541.HK:
RECEIVES FDA APPROVAL FOR IND APPLICATION OF IMM0306 FOR PHASE IB/II SLE TRIAL
Further company coverage: 1541.HK
((Reuters.Briefs@thomsonreuters.com;))
Recent news on ImmuneOnco Biopharmaceuticals (Shanghai)
See all newsBrief: Immuneonco Biopharmaceuticals (Shanghai) Receives FDA Approval For IND Application Of IMM0306 For Phase IB/II SLE Trial
Brief: Immuneonco Biopharmaceuticals (Shanghai) Says Stock Exchange Finds Immuneonco Loan Not On Normal Commercial Terms
Brief: Immuneonco Biopharmaceuticals (Shanghai) To Subscribe For Wealth Management Product For Hk$87.5 Million
Brief: ImmuneOnCo Biopharmaceuticals (Shanghai) To Repurchase H Shares In Open Market
Brief: Immuneonco Biopharmaceuticals (Shanghai)Subscribes For Hk$212 Million Wealth Management Product